OnKure Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $15.2 million, a slight improvement from the $15.9 million loss recorded in the same period of the previous year. The company’s total operating expenses decreased to $15.6 million from $17.0 million year-over-year, primarily due to a reduction in research and development costs, which fell to $11.7 million from $13.0 million. General and administrative expenses remained relatively stable, totaling $3.9 million compared to $4.0 million in the prior year.

The company experienced a significant increase in cash and cash equivalents, which rose to $192.1 million as of March 31, 2026, up from $59.1 million at the end of 2025. This increase was largely attributed to the successful completion of a private placement that generated approximately $150 million in gross proceeds. The funds are earmarked for advancing OnKure's research and development efforts, particularly for its vascular anomalies and breast cancer programs, excluding the OKI-219 candidate.

In terms of operational developments, OnKure has made strides in its clinical programs, particularly with its next-generation PI3Kα pan-mutant candidates, OKI-345 and OKI-355. The company plans to submit Investigational New Drug (IND) applications for these candidates in the first half of 2027. Additionally, the PIKture-01 trial, which evaluates the safety and efficacy of OKI-219, has completed enrollment for its initial dose escalation phases, with further evaluations planned for 2026.

As of March 31, 2026, OnKure's total liabilities stood at $14.3 million, a slight increase from $5.9 million at the end of 2025. The company’s accumulated deficit reached $229.4 million, reflecting its ongoing investment in research and development without any revenue generation from product sales. Looking ahead, OnKure anticipates continued operating losses as it advances its clinical trials and product development, emphasizing the need for additional capital to support its operations and growth strategy. The company remains focused on securing further funding through equity or debt financing, collaborations, and licensing arrangements to sustain its operations in the competitive biopharmaceutical landscape.

About OnKure Therapeutics, Inc.

OnKure Therapeutics is a biopharmaceutical company specializing in precision cancer medicines. Its core focus is developing highly selective small molecule inhibitors targeting mutated oncogenes, particularly PI3Kα mutations in breast and other cancers. The company’s pipeline includes mutation-specific therapies designed to improve efficacy and safety, with a strategic emphasis on targeted, mutation-driven treatments for underserved patient populations in oncology.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.